"10.1371_journal.pone.0106195","plos one","2014-09-04T00:00:00Z","Judy M Bradley; Paul Koker; Qiqi Deng; Petra Moroni-Zentgraf; Felix Ratjen; David E Geller; J Stuart Elborn; on behalf of the Tiotropium Cystic Fibrosis Study Group","Institute of Nursing and Health Research, University of Ulster, Ulster, Northern Ireland; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States of America; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; The Hospital for Sick Children, Toronto, Ontario, Canada; Florida State University College of Medicine, Orlando, Florida, United States of America; Centre for Infection and Immunity, Queens University Belfast, Belfast, Northern Ireland","Performed the experiments: JB PK QD PMZ FR DG JSE. Analyzed the data: JB PK QD PMZ FR DG JSE. Wrote the paper: JB PK QD PMZ FR DG JSE. Contributed to the planning and design of the trial: JB PK QD PMZ FR DG JSE.","The authors have read the journals policy, declare the following conflicts of interest, and confirm that these do not alter their adherence to PLOS ONE policies on sharing data and materials: JSE acted as a consultant for Boehringer Ingelheim and was principal investigator for this study; JMB declares no conflicts; PK, QD, and PMZ are employees of Boehringer Ingelheim; FR acts as a consultant for Boehringer Ingelheim and is the principal investigator for the phase 3 study of tiotropium in CF; DEG declares no conflicts related to bronchodilators in CF.","2014","09","Judy M Bradley","JMB",8,TRUE,NA,7,7,7,TRUE,TRUE,TRUE,1,"8",TRUE
